WWP
HRTX icon

WR Wealth Planners’s Heron Therapeutics HRTX Stock Holding History

WR Wealth Planners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$3.21K Sell
2,100
-700
-25% -$1.14K ﹤0.01% 776
2024
Q3 		$5.57K Hold
2,800
– – ﹤0.01% 723
2024
Q2 		$9.8K Sell
2,800
-500
-15% -$1.54K ﹤0.01% 596
2024
Q1 		$9.14K Buy
+3,300
New +$8.29K ﹤0.01% 615
2023
Q4 		– Sell
-3,800
Closed -$3.91K – 486
2023
Q3 		$3.91K Hold
3,800
– – ﹤0.01% 704
2023
Q2 		$4.41K Hold
3,800
– – ﹤0.01% 697
2023
Q1 		$5.74K Buy
+3,800
New +$9.52K ﹤0.01% 665

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

WR Wealth Planners's HRTX Position: Q4 2024 in Review

WR Wealth Planners reduced its Heron Therapeutics (HRTX) stake by 25% in Q4 2024, selling an estimated $1.14K and leaving 2,100 shares worth $3.21K. The position accounts for ﹤0.01% of the portfolio, ranked #776.

WR Wealth Planners first reported a position in HRTX in Q1 2023 and has held it in 7 quarters since. The position peaked at $9.8K in Q2 2024. 161 funds tracked by Wall St. Rank hold HRTX as of Q4 2024.

  • WR Wealth Planners held 2,100 shares of Heron Therapeutics worth $3.21K as of Q4 2024.
  • WR Wealth Planners sold 700 Heron Therapeutics shares in Q4 2024, an estimated $1.14K.
  • Heron Therapeutics made up ﹤0.01% of WR Wealth Planners's portfolio in Q4 2024, its #776 holding.
  • WR Wealth Planners first reported a position in Heron Therapeutics in Q1 2023 and has held it in 7 quarters since.
  • WR Wealth Planners's Heron Therapeutics position peaked at $9.8K in Q2 2024.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2024.

Based on WR Wealth Planners's 13F filing for Q4 2024, filed 5 Feb 2025.